« Back to Record
Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J.-L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., Miles, S., Gasbarrini, A., Lencioni, M., Cicalese, L., Sherman, M., Gridelli, C., Buggisch, P., Gerken, G., Schmid, R. M., Boni, C., Personeni, N., Hassoun, Z., Abbadessa, G., Schwartz, B., Von Roemeling, R., Lamar, M. E., Chen, Y., & Porta, C. (2013). Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet oncology, 14(1), 55-63. doi:10.1016/S1470-2045(12)70490-4
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/167988



